Anniina Virtanen

938 total citations
17 papers, 570 citations indexed

About

Anniina Virtanen is a scholar working on Oncology, Genetics and Rheumatology. According to data from OpenAlex, Anniina Virtanen has authored 17 papers receiving a total of 570 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 11 papers in Genetics and 5 papers in Rheumatology. Recurrent topics in Anniina Virtanen's work include Cytokine Signaling Pathways and Interactions (15 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (9 papers) and Rheumatoid Arthritis Research and Therapies (5 papers). Anniina Virtanen is often cited by papers focused on Cytokine Signaling Pathways and Interactions (15 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (9 papers) and Rheumatoid Arthritis Research and Therapies (5 papers). Anniina Virtanen collaborates with scholars based in Finland, United States and Germany. Anniina Virtanen's co-authors include Olli Silvennoinen, Juuli Raivola, T. Haikarainen, Henrik M. Hammarén, Pia Isomäki, Krista Kuuliala, Massimo Gadina, Marjatta Leirisalo‐Repo, Francesca Romana Spinelli and Ritva Peltomaa and has published in prestigious journals such as Nature Reviews Drug Discovery, Journal of Allergy and Clinical Immunology and Journal of Medicinal Chemistry.

In The Last Decade

Anniina Virtanen

16 papers receiving 556 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Anniina Virtanen Finland 10 250 151 147 128 125 17 570
Juuli Raivola Finland 9 234 0.9× 134 0.9× 104 0.7× 104 0.8× 117 0.9× 13 502
Michael A. Damore United States 16 276 1.1× 284 1.9× 124 0.8× 68 0.5× 302 2.4× 30 775
Andrea Pelosi Italy 18 202 0.8× 297 2.0× 77 0.5× 34 0.3× 489 3.9× 35 912
Anand Jillella United States 12 166 0.7× 136 0.9× 50 0.3× 113 0.9× 456 3.6× 48 841
Sachie Marubayashi United States 8 163 0.7× 123 0.8× 150 1.0× 425 3.3× 355 2.8× 13 698
Jennifer Fraszczak Canada 13 117 0.5× 415 2.7× 115 0.8× 44 0.3× 201 1.6× 23 725
Emma F. Barry Australia 14 346 1.4× 396 2.6× 45 0.3× 86 0.7× 360 2.9× 18 942
Giulia Spallone Italy 12 136 0.5× 218 1.4× 76 0.5× 44 0.3× 237 1.9× 27 609
Maria Askmyr Sweden 12 206 0.8× 203 1.3× 50 0.3× 126 1.0× 311 2.5× 23 810
Seiichi Okabe Japan 18 273 1.1× 170 1.1× 82 0.6× 287 2.2× 404 3.2× 92 969

Countries citing papers authored by Anniina Virtanen

Since Specialization
Citations

This map shows the geographic impact of Anniina Virtanen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anniina Virtanen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anniina Virtanen more than expected).

Fields of papers citing papers by Anniina Virtanen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anniina Virtanen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anniina Virtanen. The network helps show where Anniina Virtanen may publish in the future.

Co-authorship network of co-authors of Anniina Virtanen

This figure shows the co-authorship network connecting the top 25 collaborators of Anniina Virtanen. A scholar is included among the top collaborators of Anniina Virtanen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anniina Virtanen. Anniina Virtanen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Haikarainen, T., et al.. (2026). Pharmacological targeting of the JAK–STAT pathway: new concepts and emerging indications. Nature Reviews Drug Discovery.
2.
Virtanen, Anniina, et al.. (2024). Molecular basis of JAK kinase regulation guiding therapeutic approaches: Evaluating the JAK3 pseudokinase domain as a drug target. Advances in Biological Regulation. 95. 101072–101072. 3 indexed citations
3.
Virtanen, Anniina, et al.. (2024). JAK inhibitor selectivity: new opportunities, better drugs?. Nature Reviews Rheumatology. 20(10). 649–665. 32 indexed citations
4.
Haikarainen, T., Mykhailo Girych, Anniina Virtanen, et al.. (2024). Molecular basis of JAK2 activation in erythropoietin receptor and pathogenic JAK2 signaling. Science Advances. 10(10). eadl2097–eadl2097. 7 indexed citations
5.
Virtanen, Anniina, Jakub Zmajkovic, Morgane Hilpert, et al.. (2024). Functional and Structural Characterization of Clinical-Stage Janus Kinase 2 Inhibitors Identifies Determinants for Drug Selectivity. Journal of Medicinal Chemistry. 67(12). 10012–10024. 8 indexed citations
6.
Virtanen, Anniina, et al.. (2023). Differences in JAK Isoform Selectivity Among Different Types of JAK Inhibitors Evaluated for Rheumatic Diseases Through In Vitro Profiling. Arthritis & Rheumatology. 75(11). 2054–2061. 13 indexed citations
7.
Virtanen, Anniina, T. Haikarainen, Parthasarathy Sampathkumar, et al.. (2023). Identification of Novel Small Molecule Ligands for JAK2 Pseudokinase Domain. Pharmaceuticals. 16(1). 75–75. 15 indexed citations
8.
Virtanen, Anniina, et al.. (2023). Development of an enzyme-coupled activity assay for Janus kinase 2 inhibitor screening. SLAS DISCOVERY. 28(4). 180–187. 2 indexed citations
9.
Kuuliala, Krista, Anniina Virtanen, Antti Kuuliala, et al.. (2022). Tofacitinib treatment modulates the levels of several inflammation-related plasma proteins in rheumatoid arthritis and baseline levels of soluble biomarkers associate with the treatment response. Clinical & Experimental Immunology. 210(2). 141–150. 15 indexed citations
10.
Silvennoinen, Olli, T. Haikarainen, & Anniina Virtanen. (2022). Aiming for the pocket. Nature Chemical Biology. 18(12). 1296–1297. 1 indexed citations
11.
Kuuliala, Krista, Ritva Peltomaa, Anniina Virtanen, et al.. (2021). Tofacitinib Suppresses Several JAK-STAT Pathways in Rheumatoid Arthritis In Vivo and Baseline Signaling Profile Associates With Treatment Response. Frontiers in Immunology. 12. 738481–738481. 39 indexed citations
12.
Viskari, Hanna, Mikko Seppänen, Salla Keskitalo, et al.. (2021). IRF2BP2 Mutation Is Associated with Increased STAT1 and STAT5 Activation in Two Family Members with Inflammatory Conditions and Lymphopenia. Pharmaceuticals. 14(8). 797–797. 7 indexed citations
13.
Virtanen, Anniina, T. Haikarainen, Juuli Raivola, & Olli Silvennoinen. (2019). Selective JAKinibs: Prospects in Inflammatory and Autoimmune Diseases. BioDrugs. 33(1). 15–32. 204 indexed citations
14.
Hammarén, Henrik M., et al.. (2018). Janus kinase 2 activation mechanisms revealed by analysis of suppressing mutations. Journal of Allergy and Clinical Immunology. 143(4). 1549–1559.e6. 22 indexed citations
15.
Raivola, Juuli, et al.. (2018). Hyperactivation of Oncogenic JAK3 Mutants Depend on ATP Binding to the Pseudokinase Domain. Frontiers in Oncology. 8. 560–560. 15 indexed citations
16.
Hammarén, Henrik M., Anniina Virtanen, Juuli Raivola, & Olli Silvennoinen. (2018). The regulation of JAKs in cytokine signaling and its breakdown in disease. Cytokine. 118. 48–63. 156 indexed citations
17.
Hammarén, Henrik M., Anniina Virtanen, & Olli Silvennoinen. (2015). Nucleotide-binding mechanisms in pseudokinases. Bioscience Reports. 36(1). e00282–e00282. 31 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Juuli Raivola Breakdown of academic impact, for papers by Michael A. Damore Breakdown of academic impact, for papers by Andrea Pelosi Breakdown of academic impact, for papers by Anand Jillella Breakdown of academic impact, for papers by Sachie Marubayashi Breakdown of academic impact, for papers by Jennifer Fraszczak Breakdown of academic impact, for papers by Emma F. Barry Breakdown of academic impact, for papers by Giulia Spallone Breakdown of academic impact, for papers by Maria Askmyr Breakdown of academic impact, for papers by Seiichi Okabe
Rankless by CCL
2026